- ABOUT US
- CLINICAL PIPELINE
- CONTACT US
- ABOUT US
- CLINICAL PIPELINE
- CONTACT US
- JOIN OUR MAILING LIST
The conference is a three day multi-track event, which will feature over 200 innovative industry leaders from public and private companies for an in-depth discussion of the developments and trends shaping biotechnology, specialty pharmaceuticals, medical technology, healthcare facilities and services, and life sciences tools and diagnostics.
The Ladenburg 2017 Healthcare Conference will feature presentations from CEOs of an extensive range of public and private life sciences companies across the biopharmaceutical and medical technology sectors and will include one-on-one meetings with investors.
The meeting provides an opportunity for researchers, health professionals, international, national and local managers of rabies programs, wildlife biologists, laboratory personnel and other people interested in advancing knowledge of rabies surveillance, prevention and control, to meet each other, to share their successes and also to discuss the challenges to be met.
BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
This association organise a range of scientific and educational events including the ERS International Congress, the largest conference in the respiratory field. Other events include courses, research seminars, the Lung Science Conference and, Sleep and Breathing conference.
Over the past 5 years, Bioplasma World Asia has established itself as Asia’s definitive meeting place for plasma fractionators, investors, regulators and technology providers. With the mission to propel Asia towards self-sufficiency, it has brought together over 400 opinion leaders from Asia and globally from 2012 to 2015, and helped hundreds of plasma and blood products industry players to address pressing issues, share best practices and form partnerships.
Annual meeting of the informal group Partners for Rabies Prevention (PRP). The PRP is an group of key representatives for rabies within the World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), rabies vaccine manufacturing companies, academics, implementers, and Non-Governmental Organizations sat together informally, with each having a voice in discussions on how to tackle the neglect of rabies with practical ways forward.
Direct webcast link: http://public.viavid.com/index.php?id=125164
Rehovot, Israel – July 27, 2017 -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the second quarter ended June 30, 2017 prior to the open of the U.S. financial markets on Tuesday, August 1.
Kamada management will host an investment community conference call on Tuesday, August 1 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-221-9591 (from within the U.S.), 1 80 924 6042 (from Israel), or 719-325-4893 (International) and entering the conference identification number: 2753969. The call will also be webcast live on the Internet on the Company’s website at www.kamada.com.
A replay of the call will be accessible two hours after its completion through August 15 by dialing 844-512-2921 (from within the U.S.) or 412-317-6671 (from outside the U.S.) and entering the conference identification number: 2753969. The call will also be archived for 90 days on the Company’s website at www.kamada.com.
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc.’s BioScience business and now part of Shire plc) and in other counties through local distributors. In addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed a pivotal Phase 2/3 clinical trial in Europe. Kamada has also completed its Phase 2 clinical trial in the U.S. for the treatment of AAT deficiency using our proprietary inhaled AAT. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 pharmaceutical products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or other markets in which Kamada operates or intends to operate, or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Deputy CEO & Chief Financial Officer
LifeSci Advisors, LLC
The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
This program offers a unique opportunity for early career endocrinologists who treat diabetes and its complications to take advantage of small-group learning and networking experiences such as:
* Peer-to-peer engagement during small-group breakout sessions June 8-9.
* Opportunities to meet senior scientists/clinicians during receptions and “Lunch with the Expert” sessions.
* Support in navigating the primary meeting, the 77th Scientific Sessions with ongoing activities and a private lounge.
The Jefferies 2017 Global Healthcare conference will feature an extensive range of public & private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.
This year, as we mark our 15th anniversary, we are excited to introduce a new format in which we will explore and aim to fuel the innovations and trends that are shaping the future of healthcare systems and life sciences.
The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.
Kamada management will host an investment community conference call on Monday, May 9, 2016 at 8:30 a.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-803-5993 (from within the U.S.), 706-634-5454 (from outside the U.S.) and entering the conference identification number: 5573974. The call will also be webcast live on the internet on the Company’s website at www.kamada.com.
A replay of the call will be accessible two hours after its completion through May 15, 2016 by dialing 855-859-2056 (from within the U.S.) or 404-537-3406 (from outside the U.S.) and entering the conference identification number: 5573974. The call will also be archived for 90 days on the Company’s website at www.kamada.com.
BIO-Europe Spring® is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking.
The IPPC is the premier conference in Europe for the plasma protein therapeutics industry. Take advantage of this event and join policy makers, regulators, industry leaders, physicians, scientists, and patient representatives from around the globe.
NESS ZIONA, Israel (February 5, 2016) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company will participate at the Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Amir London, the Company’s Chief Executive Officer, will present a corporate overview on February 11th from 12:30PM to 12:55PM.
Mr. London’s slide presentation will be available on the Company’s website at www.kamada.com
Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
Our therapeutic workshops feature MDs, CSOs and industry analysts discussing the latest information on pipeline innovation for breakthrough therapeutic topics in biopharma. Seasoned industry executives and analysts delve into timely and relevant business models, deal-making and investment trends on our business roundtables.
NESS ZIONA, Israel (January 27, 2016) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and twelve months ended December 31, 2015 prior to the open of the U.S. stock market open on Tuesday, February 2, 2016.
Kamada management will host an investment community conference call on Tuesday, February 2, 2016 at 8:30 a.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-803-5993 (from within the U.S.), 706-634-5454 (from outside the U.S.) or 1-809-315-362 (toll-free from Israel) and entering the conference identification number: 38830870.
A replay of the call will be accessible two hours after its completion through February 8, 2016 by dialing 855-859-2056 (from within the U.S.) or 404-537-3406 (from outside the U.S.) and entering the conference identification number: 38830870.
J.P. Morgan conferences bring together corporate leaders, financial sponsors and institutional investors to explore market and sector trends.
About the Bio Europe Spring Conference, where the global biotech industry comes to partner.
BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities.
The 33rd Annual J.P. Morgan Healthcare Conference & Biotech Showcase 2015 will be held January 12-15, 2014 in San Francisco, California.
The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.
Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.
- See more at: http://globalbiodefense.com/event/j-p-morgan-annual-healthcare-conference/#sthash.fHzinGct.dpuf
The 2013 conference is set to feature public and private leading global healthcare companies within the areas of pharmaceuticals, biotech, generics, medtech and healthcare services from the US, Central and Eastern Europe, Latin America, India, China, Japan, Egypt, Israel and Russia.
This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
Kamada management will host an investment community conference call on Tuesday, October 29, 2013 beginning at 8:30 a.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-803-5993 (from within the U.S.) or 706-634-5454 (from outside the U.S.) or 1-809-315-362 (toll-free from Israel) and entering passcode 87555865. The call also will be broadcast live on the Internet at www.streetevents.com, www.earnings.com and www.kamada.com.
A replay of the conference call will be accessible two hours after its completion through November 4, 2013 by dialing (855) 859-2056 (from within the U.S.) or (404) 537-3406 (from outside the U.S.) and entering passcode 87555865. The call will also be archived for 90 days at www.streetevents.com, www.earnings.com and www.kamada.com.
Kamada management will host an investment community conference call on 1.8.2013, beginning at 10:00 a.m. Eastern time to discuss Q2 results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing (888) 803-5993 (from within the U.S.) or (706) 634-5454 (from outside the U.S.) and entering passcode 21054403. The call also will be broadcast live on the Internet at www.streetevents.com, www.earnings.com and www.kamada.com.
People worldwide rely on access to plasma-derived and recombinant analog therapies to improve and save their lives, and this is an opportunity for all stakeholders to come together. Consumers, physicians, caregivers, regulators and policymakers, and industry representatives should attend. Key issues facing the industry today and in the future will be presented.
IATI BIOMED 2013 follows the success of previous annual conferences where the Israeli Life Sciences industry hosted 6,000 industry players, engineers and scientists with approximately 1,000 participants from over 40 countries and in excess of 3,500 one-on-one meetings.
Kamada's presentation, on new clinical developments for Alpha-1 Antitrypsin, will take place at June 10, 4:50pm.
The National Conference is the largest gathering of Alphas and families in the world, with an expected attendance of more than 600 people,
The annual International Conference of the American Thoracic Society is one of the largest gatherings of pulmonary, critical care and sleep clinicians and researchers in the world.
IPPC is the primary international congress for all stakeholders of plasma protein therapies.
Sessions will feature topics such as clinical developments, patient access, self-sufficiency, regulatory considerations, plasma collection, health policy and much more.
Kamada to participate at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in ParisFeb. 26 - Mar. 1, 2013 / Paris, France
ATTD 2013 is an innovative conference that will bring together the world’s leading researchers and clinicians for a lively exchange of ideas and information related to the treatment and prevention of diabetes and related illnesses.
The Israeli President will presents the outstanding exporter award to Kamada on its performance in 2011.
The Deloitte Brightman Almagor Zohar Technology Fast 50 Program annually recognizes and honors the 50 private and publicly held fastest growing technology companies in Israel, based on percentage revenue growth over a five-year period.